Quoin Pharmaceuticals, LTD S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Quoin Pharmaceuticals is offering up to 19,230,769 ordinary shares represented by American Depositary Shares (ADSs) along with warrants in a reasonable best efforts offering.
NASDAQ
S-1: Quoin Pharmaceuticals Seeks Up to $45 Million in Public Offering to Advance Rare Disease Pipeline
Quoin Pharmaceuticals is launching a public offering of ordinary shares, pre-funded warrants, and common warrants to raise up to $45 million for general corporate purposes and clinical development.
NASDAQ
Quoin Pharmaceuticals launches a best efforts offering of ADSs and warrants, aiming to raise capital for general corporate purposes, including research and development of treatments for rare skin diseases.
NASDAQ
Quoin Pharmaceuticals is launching a public offering of ADSs and warrants, aiming to raise up to $21 million to further its research and development efforts in rare skin diseases.